Brief: Evelo Biosciences Announces Fourth Quarter And Full Year 2022 Financial Results And Business Highlights

Evelo Biosciences

16/03/2023 11:36

March 16 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
    * IN FEBRUARY 2023, EVELO BEGAN DOSING PSORIASIS PATIENTS IN
PHASE
2 PORTION OF TRIAL, WITH DATA EXPECTED 2H 2023
    * AS OF DECEMBER 31, 2022, CASH AND CASH EQUIVALENTS WERE
$47.9
MILLION
    * QTRLY NET LOSS PER SHARE $0.21
    * Q4 EARNINGS PER SHARE VIEW $-0.28 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX7GlRpJ 
Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;;))